insights_auto
FARN niyə bu qədər düşüb: 4,11%?
Ətraflı araşdırınchevron_right
FARN:LON
Faron Pharmaceuticals Oy
35,00 GBX
arrow_downward
-4,11%(-1,50) 1D
9 okt, 16:30:00 GMT+1 · GBX
search
Bütün simvollar
| Simvol | Qiymət | Dəyişiklik | % Dəyişiklik |
|---|
insights_autoFARN üçün ən vacib statistik məlumatlar yaradılır...
Açın
35,00 GBX
Yüksək
38,00 GBX
Aşağı
35,00 GBX
Bazar kapitalizasiyası
73,96 mln
Ortalama həcm
45,22K
Həcm
15,60K
52 həftəlik ən yüksək
193,58 GBX
52 həftəlik ən aşağı
34,00 GBX
EPS
-0,10 GBX
Dövriyyədəki səhmlər
31,03 mln
İşçilərin sayı
36
Açın
35,00 GBX
Yüksək
38,00 GBX
Aşağı
35,00 GBX
Bazar kapitalizasiyası
73,96 mln
Ortalama həcm
45,22K
Həcm
15,60K
52 həftəlik ən yüksək
193,58 GBX
52 həftəlik ən aşağı
34,00 GBX
EPS
-0,10 GBX
Dövriyyədəki səhmlər
31,03 mln
İşçilərin sayı
36
Xəbər materialları
Veb mənbələri və xəbər partnyorlarından
The Motley Fool
·
4 dəqiqə öncə
The S&P 500 Just Hit a Record High -- Here's How Much Higher It Can Climb, According to the Wall Street Consensus
MarketBeat
·
1 saat öncə
Iron Horse Acquisitions II Corp. (NASDAQ:IRHO) Stock Short Interest Report for September
Barchart.com
·
49 dəqiqə öncə
Gold & SP 500 Futures Update 10/11/26
Yahoo Finance
·
3 saat öncə
Pokémon Cards Just Crushed Bitcoin, Gold and the S&P 500 With 150% Returns
Profil
Faron Pharmaceuticals is a Finnish drug discovery and development company based in Turku, Finland.
The company was founded in 2003 by a group led by Markku Jalkanen, who now acts as the company's Chief Executive Officer. It specialises in the development of treatments for acute organ traumas, vascular damage and cancer immunotherapy.
Its lead product Traumakine has been developed to treat acute respiratory distress syndrome. It is currently undergoing international phase III clinical trials after an open-label, early-phase trial showed promising results in the treatment patients with ARDS. The drug is known to function by enhancing lung CD73 expression and increasing production of anti-inflammatory adenosine, such that vascular leaking and escalation of inflammation are reduced. The U.S. Food and Drug Administration FDA has accepted the proposed protocol design for the next Traumakine study in March 2020. The phase III study is a comparison of efficacy in the treatment of patients with ARDS.
In 2020 Traumakine was selected to take part in the WHO Solidarity trial and REMAP-CAP trials to find drugs for the symptoms of Covid_19. Wikipedia
Faron Pharmaceuticals Oy haqqında